PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76), BIOD: 1.36 (-0.04)
BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa
GlobeNewswire - Wed Dec 24, 12:15PM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10)
BioMarin CEO Sees Big Future For Prosensa Drug
at Investor's Business Daily - Tue Dec 23, 3:11PM CST
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called...
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)
Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 6:07PM CST
Pfizer (PFE) has moved its experimental Duchenne muscular dystrophy treatment into a phase II study.
RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), MYL: 56.97 (+0.39)
Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST
ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)
3 Traits of the Best Healthcare Stocks in 2014
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 15, 6:20AM CST
Source: MercK & Co., Just when it looked as though the stock market couldn't possibly finish the year higher, after its swoon in October, it proved the naysayers wrong. As of this writing, the S&P 500 has risen by 11% for the year, a tad...
AVNR: 16.91 (+0.01), RNA: 18.76 (+0.10), ACHN: 13.06 (+1.22), EXAS: 27.60 (+0.39), AGIO: 109.67 (+2.45)
PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Fri Dec 12, 11:40AM CST
Rigrodsky & Long, P.A.:
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10)
Prosensa Holding (RNA) Upgraded From Sell to Hold
at The Street - Fri Dec 12, 6:10AM CST
Prosensa Holding (RNA) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
RNA: 18.76 (+0.10)
The Nominees for Best Biotechnology Co. CEO of 2014 Are...
at The Street - Fri Dec 12, 5:05AM CST
The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO
BLUE: 88.76 (+3.23), RNA: 18.76 (+0.10), EXAS: 27.60 (+0.39), AGIO: 109.67 (+2.45)
Prosensa Wins Scrip 'Biotech Company of the Year' 2014 Award
GlobeNewswire - Mon Dec 08, 7:17AM CST
Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with a high unmet medical need, is delighted to have won the Scrip 'Biotech Company of the Year' Award for 2014, announced last week in London, UK.
RNA: 18.76 (+0.10)
Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta
at The Street - Fri Dec 05, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.59 (unch), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47)
RNA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Prosensa Holding N.V. in Connection With the Fairness of the Sale of the Company to BioMarin Pharmaceutical Inc.
Business Wire - Thu Dec 04, 11:11AM CST
Levi & Korsinsky is investigating the Board of Directors of Prosensa Holding N.V. ("Prosensa" or "the Company"
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10)
RNA INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Prosensa Holding N.V. in Connection With the Fairness of the Sale of the Company to BioMarin Pharmaceutical Inc. -- RNA
PR Newswire - Thu Dec 04, 11:05AM CST
Levi & Korsinsky is investigating the Board of Directors of Prosensa Holding N.V. ("Prosensa" or "the Company"
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10)
Prosensa Holding N.V. Acquisition By BioMarin Pharmaceutical Inc. May Not Be In The Best Interests of RNA Shareholders
PR Newswire - Wed Dec 03, 3:11PM CST
The fairness of the proposed acquisition of Prosensa Holding N.V. ("RNA" or the "Company"
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10)
Merger Opportunity: BioMarin To Adquire Prosensa
Maudes Capital - at Seeking Alpha - Wed Dec 03, 6:57AM CST
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), GSK: 42.85 (+0.11)
Jim Cramer's Five Best Stock Picks for the Biotech Sector
at The Street - Tue Dec 02, 10:11AM CST
TheStreet's Jim Cramer has selected 12 sectors where he thinks investors should put their money. Biotech stocks have had a "monstrous" year. Here are Cramer's best picks.
BIIB: 340.89 (+5.13), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), ISIS: 59.49 (+1.88), AGIO: 109.67 (+2.45), GSK: 42.85 (+0.11), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Prosensa Holding N.V. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Dec 01, 3:32PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Prosensa Holding N.V. ("Prosensa" or the "Company"
RNA: 18.76 (+0.10)